Ignite Creation Date:
2024-05-06 @ 1:24 AM
Last Modification Date:
2024-10-26 @ 11:03 AM
Study NCT ID:
NCT01804140
Status:
COMPLETED
Last Update Posted:
2016-11-02
First Post:
2013-02-26
Brief Title:
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf Vemurafenib
Sponsor:
Genentech Inc
Organization:
Genentech Inc
Study Overview
Official Title:
Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib
Status:
COMPLETED
Status Verified Date:
2016-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a screening study to detect BRAF V600 mutation-positive patients for enrollment into clinical research studies of Zelboraf vemurafenib Tumor samples will be collected and analyzed from eligible patients with solid tumors other than metastatic melanoma or papillary thyroid cancer or multiple myeloma All institutions with identified patients as defined by this screening protocol will have potential access to the separate vemurafenib protocol MO28072
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None